Compounds > valine

valine and quinazolines

valine has been researched along with quinazolines in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19901 (11.11)18.7374
1990's0 (0.00)18.2507
2000's4 (44.44)29.6817
2010's4 (44.44)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ebata, M; Miyazaki, K; Otsuka, H1
Anaganti, S; Billaud, M; Carlomagno, F; Fusco, A; Guida, T; Ryan, AJ; Santoro, M; Vecchio, G1
Asahina, H; Dosaka-Akita, H; Kinoshita, I; Nishimura, M; Yamazaki, K; Yokouchi, H1
Fu, X; Ho, WT; Ishii, T; Li, Q; Li, Z; Xing, S; Xu, M; Zhao, ZJ1
Dasmahapatra, B; Demma, MJ; Naumann, U; Roth, P; Weinmann, L; Weller, M; Wischhusen, J1
Teh, BW; Worth, LJ1
Chough, C; Joung, M; Kim, ES; Lim, JW; Maeng, HJ; Shim, CK; Shim, WS1
Cheng, Z; Li, P; Liu, Z; Zhu, Q1
Al-Kali, A; Cherry, M; Ghabache, B; Khawandanah, M; Ozer, H; Selby, G; Srour, S; Zhao, ZJ1

Trials

1 trial(s) available for valine and quinazolines

ArticleYear
Erlotinib is not effective in patients with JAK2V617F-positive polycythemia vera.
    Annals of hematology, 2015, Volume: 94, Issue:4

    Topics: Adult; Aged; Amino Acid Substitution; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Humans; Janus Kinase 2; Male; Middle Aged; Phenylalanine; Polycythemia Vera; Quinazolines; Treatment Outcome; Valine

2015

Other Studies

8 other study(ies) available for valine and quinazolines

ArticleYear
Studi on siomycin. II. The composition and degradation products of siomycin A.
    The Journal of antibiotics, 1969, Volume: 22, Issue:9

    Topics: Acetaldehyde; Alanine; Amino Acids; Anti-Bacterial Agents; Butyrates; Carbon; Chemical Phenomena; Chemistry; Cysteine; Optical Rotatory Dispersion; Oxidation-Reduction; Propionates; Pyruvates; Quinazolines; Thiazoles; Threonine; Valine

1969
Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.
    Oncogene, 2004, Aug-12, Volume: 23, Issue:36

    Topics: Carcinoma, Medullary; Catalytic Domain; Cell Line; Drug Resistance; Enzyme Inhibitors; Mitogens; Piperidines; Point Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Pyrazoles; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Thyroid Neoplasms; Valine

2004
Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L.
    Lung cancer (Amsterdam, Netherlands), 2006, Volume: 54, Issue:3

    Topics: Adenocarcinoma; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Isoleucine; Leucine; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Serine; Valine

2006
Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth.
    The Journal of biological chemistry, 2007, Feb-09, Volume: 282, Issue:6

    Topics: Amino Acid Substitution; Animals; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Enzyme Activation; Erlotinib Hydrochloride; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Janus Kinase 2; Jurkat Cells; Mice; Phenylalanine; Polycythemia Vera; Protein Kinase Inhibitors; Quinazolines; Valine

2007
A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
    Cell death and differentiation, 2008, Volume: 15, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Aza Compounds; Brain Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Electrophoretic Mobility Shift Assay; Gene Expression Regulation, Neoplastic; Glioma; Humans; Mutation; Promoter Regions, Genetic; Quinazolines; Rats; Rats, Sprague-Dawley; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA Interference; RNA, Messenger; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Transfection; Tumor Suppressor Protein p53; Up-Regulation; Valine

2008
Disseminated herpes simplex virus infection following epidermal growth factor tyrosine kinase inhibitor therapy for non-small-cell lung carcinoma.
    Internal medicine journal, 2012, Volume: 42, Issue:11

    Topics: Acyclovir; Afatinib; Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Non-Small-Cell Lung; Cystitis; ErbB Receptors; Esophagitis; Hematuria; Herpes Simplex; Humans; Intestinal Perforation; Lung Neoplasms; Male; Molecular Targeted Therapy; Neoplasm Proteins; Peritonitis; Protein Kinase Inhibitors; Quinazolines; Valacyclovir; Valine; Viremia; Virus Activation

2012
Addition of amino acid moieties to lapatinib increases the anti-cancer effect via amino acid transporters.
    Biopharmaceutics & drug disposition, 2014, Volume: 35, Issue:1

    Topics: Amino Acid Transport Systems; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dogs; Glutamine; Humans; Lapatinib; Madin Darby Canine Kidney Cells; Protein Kinase Inhibitors; Quinazolines; Tyrosine; Valine

2014
Drug interaction studies reveal that simotinib upregulates intestinal absorption by increasing the paracellular permeability of intestinal epithelial cells.
    Drug metabolism and pharmacokinetics, 2014, Volume: 29, Issue:4

    Topics: Acyclovir; Anti-Infective Agents; Body Weight; Caco-2 Cells; Cefaclor; Dose-Response Relationship, Drug; Drug Interactions; Humans; Intestinal Absorption; Intestinal Mucosa; Microfilament Proteins; Permeability; Quinazolines; Spiro Compounds; Up-Regulation; Valacyclovir; Valine

2014